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ABSTRACT
In vitro assays that evaluate CD8+ T cell-mediated cytotoxicity are important to aid in the development of novel
therapeutic approaches to enhance anti-tumor immune responses. Here, we describe a novel cytotoxicity co-
culture assay that circumvents the problem of highly variable allogeneic responses and obviates the con-
straints of HLA-restriction between effector and target cells. We show that this assay can be easily applied to
a panel of tumor cell lines to provide additional insights into intrinsic drivers of sensitivity/resistance to T cell-
mediated killing, and to evaluate the impact of targeted therapies on both tumor and T cell compartments.
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Immunotherapy is now established as a standard of care for
many cancer types.1,2 Despite this rapid progress, a greater
understanding of intrinsic or adaptive mechanisms of resis-
tance to immunotherapy is required to increase the propor-
tion of responding patients, and durability of responses.
Furthermore, there is now a more urgent need to better
characterize how targeted therapies, designed to specifically
affect tumor cells, may impact the anti-cancer immune
response to identify productive combinations and avoid
potentially antagonistic drug combinations.
CD8+ cytotoxic T cells are considered as the principal cellular
mediators of anti-tumor immunity due to their capacity for
specific recognition of tumor-associated antigens (TAA) and
intrinsic cytotoxic potential.3 Therefore, in vitro assays that
permit evaluation of T cell cytotoxicity against tumor cells can
be used to determinemechanisms of sensitivity/resistance and to
screen novel agents that maymodulate the outcome of the T cell/
tumor cell interaction, providing important translational
insights. T cells recognize peptide antigens in the context of the
major histocompatibility complex (MHC) through their T cell
receptors (TCR) providing ‘signal 1ʹ. Costimulatory proteins
provide ‘signal 2ʹ, via the CD28 co-receptor protein expressed
on the surface of T cells. Activation of CD8+ cytotoxic
T lymphocytes (CTLs) leads to target cell apoptosis through
the release of lytic granules or via alternative mechanisms such
as the Fas pathway, or cytokine release.4 As such, most estab-
lished in vitroT cell cytotoxicity assays depend on T cell antigen-
specific recognition via tumorMHC-TCR engagement, and thus
are either human leukocyte antigen (HLA) restricted or rely on
alloreactivity.5,6 Autologous assays are challenging given the
limitations on the numbers of HLA-matched donor T cells that
can be sourced.7 Moreover, allogeneic assay systems are intrin-
sically variable from donor to donor.8 Therefore, it is difficult to
assess a T cell response across a range of tumor cells with distinct
genotypes, to investigate how these perturbations may impact
sensitivity to T cell cytotoxicity.
We have developed a method for generating tumor cell lines
that express a fragment of anti-CD3 antibody on the cell
membrane.9 These engineered cells provide ‘signal 1ʹ to T cells
leading to T cell activation in an MHC- and antigen-independent
manner, enabling T cells to be active in a redirected T cell-
mediated cytotoxicity assay. This system allows for interrogation
of intrinsic mechanisms of sensitivity/resistance to T cell-
mediated cytotoxicity across a range of cell lines. In addition, we
show that this versatile co-culture system can also be used to
evaluate the activity of targeted therapies on both the tumor and
T cell compartments across multiple donors.
Results
Optimizing CD8+ T cells for tumor cell cytotoxicity assays
To optimize our cytotoxicity assay, we first determined how
in vitro restimulation conditions would impact the cytotoxic
capacity and phenotype of CD8+ T cells. We used anti-CD3
redirected cytotoxicity against P815 mouse mastocytoma cells.
These P815 cells express Fcγ-receptors, thus providing ‘signal 1ʹ
and leading to CD8+T cell activation and cytotoxicity. This assess-
ment was used to guide subsequent experiments in the anti-CD3-
expressing engineered tumor cell system used. Our co-culture
assay is based on two rounds of anti-CD3/CD28 stimulation of
isolated primary CD8+ T cells, which are then co-cultured with
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DiO labeled tumor cells at various time points. After which,
staining with a LIVE/DEAD Violet viability dye allows for flow
cytometry analysis of live DiO+ Violet− tumor cells within the co-
culture (Supplementary Fig. S1). Our data demonstrate that
this second round of restimulation of CD8+ T cells following
in vitro expansion with anti-CD3/CD28 dynabeads, 5 days prior
to co-culture in a cytotoxicity assay, enhanced effector function
(Figure 1a). At the highest effector: target (E: T) ratio of 10:1
versus the control 0 E: T ratio, we observed approximately 30%
P815 cytotoxicity in the presence of soluble anti-CD3, when
compared to almost no effect with the isotype control.
Comparatively, P815 cytotoxicity was increased to 45% in the co-
culture at the 10:1 E: T ratio, following restimulation of the CD8+
T cells (Figure 1a). This increased cytotoxicity was commensurate
with an observed differentiation of the restimulated CD8+ T cells
towards an effector phenotype (increased CD45RO expression,
decreasedCD45RA expression (Figure 1b,c), and decreased CCR7
expression (Figure 1d,e) when compared to pre-stimulation).
Using this expansion/reactivation protocol, we were able to
generate sufficient populations of effectors T cells with robust
cytotoxic activity for use in cytotoxicity assays.
Generation of anti-CD3 expressing tumor cell lines
Allogeneic T cell cytotoxicity assays are highly variable.8
Therefore, TCR triggering through CD3 is an effective method
for circumventing MHC/TCR alloreactivity and increasing the
number of cytotoxic synapses between T cells and tumor cells.
However, in contrast to P815 cells, most solid tumor cells lack Fc
receptors and therefore TCR triggering at the synapse of T and
Figure 1. Optimizing CD8+ T cells for tumor cell cytotoxicity assays.
a. Percentages of live P815 target cells in the presence of soluble anti-CD3 antibody or isotype control antibody in 4-h co-cultures with CD8+ T cells before (left, day
10 after initial activation with anti-CD3/CD28 dynabeads) and after (right, day 15) a second round of stimulation with anti-CD3/CD28 dynabeads (performed on day
10). b. CD45RO and CD45RA expression by flow cytometry on naïve, unstimulated CD8 + T cells, CD8+ T cells on day 10 before and day 15 after restimulation c.
Percentages of CD45RO+CD45RA− CD8+T cells across multiple donors, before and after restimulation by flow cytometry. d. Representative histogram showing CCR7
expression by flow cytometry in CD8 + T cells before and after restimulation. e. MFI of CCR7 expression in CD8+ T cells across multiple donors, before and after
restimulation. Data is representative of two donors from three independent experiments (mean ± SEM). E: T ratio = effector: target ratio; MFI = Mean Fluorescence
Intensity; FMO = fluorescence minus one control. *P < 0.05, and ***P < 0.0005 and ****P < 0.0001, significant difference of % live cells between isotype and anti-CD3
at each E: T ratio, assessed by two-way ANOVA and Sidak‘s multiple comparison test.
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tumor cells cannot be facilitated by crosslinking via addition of
anti-CD3 antibody. Therefore, we generated lentiviral constructs
encoding an anti-CD3 antibody fragment fused to the transmem-
brane domain of CD149 (Figure 2a). Three EGFR mutant
(EGFRm) NSCLC cell lines; PC-9, NCI-H1975, and NCI-
H3255, were transduced to express this scFV-CD3(OKT3)-CD
14 construct to activate CD8+ T cells via their TCR and thus lead
to cytotoxicity of the tumor cells (Figure 2b). The workflow for
cell line transduction is provided in Figure 2c. Briefly, the anti-CD
3 expressing tumor cells were transduced using viral supernatants
from transfected 293T/17 cells. Multiplicity of infection (MOI) of
both 1 and 10 were tested and based on sufficient transduction
efficiency being achieved, cells transduced at an MOI of 1 were
used for all experiments. Antibiotic selection was used to select for
and maintain expression of the anti-CD3 scFv construct and
transduced cells sorted by flow cytometry based on CD14 expres-
sion. Using an anti-IgG antibody (H + L), which binds to the
heavy and light chains of the anti-CD3 scFV,9 we examined the
expression of cell surface anti-CD3 and found that all transduced
cell lines expressed high levels of anti-CD3 relative to non-
transduced parental controls (Figure 2d). Using this method, cell
surface expression of anti-CD3 was routinely confirmed on the
tumor cells lines.
Co-culture of CD8+ T cells with tumor cells expressing
anti-CD3 results in T cell-mediated cytotoxicity
To validate the model, anti-CD3 expressing tumor cell lines were
co-cultured with restimulated CD8+ effector T cells. T cell-
mediated cytotoxicity against all three cell lines was evaluated at
4 and 18 h in comparison to P815 control cells, whichwere used as
an indicator of T cell effector function due to their high
susceptibility to T cell cytotoxicity as previously shown. Using
our flow cytometry-based readout to analyse live tumor cells in
these co-cultures, we observed that in contrast to control P815
cells (where CD3 stimulation is regulated by soluble anti-CD3
antibody), the window of T cell-mediated cytotoxicity in the anti-
CD3 expressing NSCLC cell lines was small at 4 h (roughly, 3% in
PC-9, 11% in NCI-H1975 and 17% in NCI-H3255) (as calculated
by differences in cytotoxicity at 0 to 10:1 E: T ratio) (Figure 3a).
However, by 18 h, the magnitude of T cell-mediated cytotoxicity
was greater in both the P815 cells and in PC-9, NCI-H1975 and
NCI-H3255 EGFRm cell lines (Figure 3b). As expected, the level
of cytotoxicity was proportional to the E: T ratio. In these 18h co-
cultures, the range of tumor cell death varied from 30% to 70% at
the lowest E: T ratio (1:1) to 80–100% at the highest E: T ratio
(10:1). We also show that the observed trends in cytotoxicity
across all three EGFRm cell lines in 18h co-cultures, is replicated
across multiple donors and experiments tested, with some varia-
bility depending on donor responses (Supplementary Fig. S2).
Each cell line displayed slight variation in their intrinsic sensitivity
to cytotoxicity in this assay. To explore this further, we also
evaluated T cell function following co-culture with the different
tumor cell lines, by measuring granzyme B and PD-1 expression
by intracellular staining of CD8+ T cells and flow cytometry
(Figure 3c,d). Granzyme B production (Figure 3c) and PD-1
(Figure 3d) expression were induced in CD8+ T cells by all three
tumor cell lines, compared to CD8+ T cells alone, although
significance was only observed in PC-9 and NCI-H1975 cells
lines at all E: T ratios. However, each cell line induced differing
total levels of granzyme B and PD-1, with T cells co-cultured with
PC-9 tumor cells expressing the highest level of granzyme
B (Figure 3c), while T cells co-culture with NCI-H1975 tumor




Figure 2. Generation of anti-CD3 expressing tumor cell lines.
a. Schematic of anti-CD3-scFV-CD14 expression construct design. b. Schematic of anti-CD3-scFV-CD14 expressing engineered tumor cells activating CD8+ T cells via the T cell
receptor (TCR), leading to T cell-mediated cytotoxicity c. Workflow of experimental steps to generate stable anti-CD3-scFV-CD14 expressing tumor cell lines for use in co-
culture assays with activated CD8+ T cells. d. Representative histograms showing anti-CD3 expression on parental (light grey histograms) and transduced (dark grey
histograms) PC-9, NCI-H1975 and NCI-H3255 EGFRm NSCLC cell lines, as measured by flow cytometry after surface staining with anti-IgG. Data are representative of three
independent experiments. MOI = multiplicity of infection; EGFRm = epidermal growth factor receptor mutant; NSCLC = non-small cell lung carcinoma.
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Expression levels of anti-CD3 influence the extent of
tumor cell cytotoxicity by T cells
As expected, the level of anti-CD3 expression influences the
magnitude of T cell-mediated cytotoxicity. Using a flow cyto-
metric gating system, we were able to demonstrate this by gating
on cells with high, medium and low expression using anti-IgG (H
+ L) staining (Figure 4a). Using, PC-9 cells (transduced with anti-
CD3), we show that expression of anti-CD3 correlates with cyto-
toxicity, especially at higher E: T ratios (Figure 4b). Therefore, this
gating can be applied to potentially explore the impact of TCR
signal agonism on cytotoxic responses. Moreover, to circumvent
this issue when comparing across cell lines with different levels of
anti-CD3 expression (Supplementary Fig. S3A), this gating strat-
egy can be specifically applied (Supplementary Fig. S3B) to select
cells with similar levels of anti-CD3 expression (Supplementary
Fig. S3C). This method can be used to control for variability in
transduction efficiencies, thus permitting the analysis of
a population of cells with highly overlapping expression levels of
anti-CD3 and allowing for direct comparisons of relative cyto-
toxicity across multiple cell lines (Supplementary Fig. S3D).
Measurements of IFN-ɣ and early tumor cell apoptotic
events provide additional sensitive pharmacodynamic
endpoints in this assay system
On recognition of peptide-MHC complexes on target cells,
CD8+ T cells trigger programmed cell death of target cells.10
Therefore, we wanted to characterize the mode of cell death in
the anti-CD3-transduced tumor cells beyond evaluating over-
all viability in co-cultures. We examined cell death in our co-
cultures using both direct DiO labelling of mock (cell lines
transduced with empty vector controls) and anti-CD3 trans-
duced tumor cells (Figure 5a) and using annexin-V and
7-amino actinomycin D (7-AAD) staining of co-cultures
with anti-CD3 expressing cells only, as a readout to evaluate
apoptosis (Figure 5b). We found that anti-CD3 transduced
tumor cells undergo significantly more T cell-mediated cyto-
toxicity than their empty vector mock control counterparts
(Figure 5a) and that there is an induction of early apoptotic
tumor cells (annexin-V+ 7-AAD−) in the co-cultures with the
anti-CD3 expressing NSCLC cell lines (Figure 5b). Moreover,
measurement of IFN-ɣ in the co-culture supernatants of mock
and anti-CD3 tumor cells also correlated with the level of
tumor cell cytotoxicity and E: T ratios (Figure 5c) and was
sufficiently sensitive to be a pharmacodynamic readout of
T cell activity.
Investigating the impact of targeted therapies on T
cell-mediated cytotoxicity using the CD3-expressing
tumor cell co-culture system
Evaluating the potential impact of targeted therapies on both
tumor and T cell responses is becoming increasingly important
as immunotherapy becomes part of the standard of care for
many cancer types. Targeted therapies may enhance or have
antagonistic effects on T cell-mediated cytotoxicity. Moreover,
Figure 3. Co-culture of CD8+ T cells with tumor cells expressing anti-CD3 results in target cell T cell-mediated cytotoxicity.
a. Percentages of live P815 cells (in the presence of soluble anti-CD3 antibody or isotype control antibody) and PC-9, NCI-H1975 and NCI-H3255 anti-CD3 engineered
EGFRm cell lines in co-cultures with restimulated CD8+ T cells for 4 h. b. Percentages of live P815 cells and anti-CD3 expressing EGFRm cell lines in co-cultures with
restimulated CD8+ T cells for 18 h. MFI of c. Granzyme B expression and d. PD-1 expression in CD8+ T cells alone and in co-cultures with anti-CD3 expressing PC-9,
NCI-H1975 and NCI-H3255 EGFRm cell lines. Data are representative of two donors from three independent experiments (mean ± SEM). EGFRm = epidermal growth
factor receptor mutant; GzmB = granzyme B; MFI = Mean Fluorescence Intensity. *P < 0.05, **P < 0.01, ***P < 0.0005 and ****P < 0.0001, significant difference of %
live cells between isotype and anti-CD3 at each E: T ratio (Figure 3a,b) and MFI of granzyme B and PD-1 between T cells only and at each E: T ratio (Figure 3c,d),
assessed by two-way ANOVA with Sidak‘s multiple comparison test and unpaired parametric two-tailed t-test, respectively.
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evaluating how combinations of distinct immunotherapies may
converge on cytotoxic potential against tumor cells is poorly
understood.11 Therefore, using the PC-9 EGFRm anti-CD3
expressing NSCLC cell line as a model, we next characterized
the effects of EGFR tyrosine kinase inhibitors (TKIs) on T cell
cytotoxic potential. PC-9 cells harbour an EGFR activating
mutation due to a deletion in exon 1912,13 and are therefore
sensitive to first and third generation EGFR TKIs, gefitinib and
osimertinib, respectively.14 Pre-treatment of PC-9 cells with
gefitinib and osimertinib, at clinically relevant doses and main-
tenance of these concentrations in co-cultures, resulted in an
increase in the amount of tumor cell death observed in co-
cultures with both drugs, compared to DMSO control
(Figure 6a). This increase in tumor cell death was mirrored in
the no T cell controls (0 E: T ratio) and increased the amount of
tumor cell death evaluated in combination with effector CD8+
T cells (Figure 6a). These observations were also confirmed
using the anti-CD3 expressing NCI-H3255 EGFR mutant
NSCLC cell line (Supplementary Fig. S4). These findings suggest
that inhibition of EGFR signaling, whilst capable of reducing the
survival of EGFRm NSCLC cells, does not negatively influence
T cell-mediated cytotoxicity.
Adenosine has been shown to have suppressive effects on
T cell function and is a component of some tumor
microenvironments.15,16 The addition of SCH58261;
a selective inhibitor of A2aR receptor,16 was not found to
directly impact tumor cell viability (0 E: T ratio), but was
found to significantly enhance T cell-mediated cytotoxicity
against anti-CD3 transduced PC-9 cells in the presence of
AMP, when compared to DMSO control, across all E:
T ratios tested (Figure 6b). Moreover, we show this increase
in tumor cell death can be consistently observed across
donors (Supplementary Fig. S5). As such, these data suggest
that targeting the adenosine pathway can directly modulate
CD8+ T cell cytotoxic function.
To further characterize the assay, we next investigated the
effects of dasatinib, a potent inhibitor of the Src family kinases
including Lck which is critical for mediating T-cell signaling
downstream of the TCR.17,18 Our assay demonstrated
a significant reduction in T cell-mediated cytotoxicity against
anti-CD3 expressing PC-9 cells in the presence of 12.5 nM
dasatinib compared to DMSO control and revealed that dasati-
nib had no effect on tumor cells alone, in the absence of T cells
(0 E: T ratio) (Figure 6c). Furthermore, a dose-response of
dasatinib from 0 to 100 nM in co-cultures with anti-CD3
expressing PC-9 cells showed that concentrations of 25, 50 and
100 nM dasatinib further significantly reduced T cell-mediated
cytotoxicity of PC-9 cells (Supplementary Fig. S6). These find-
ings confirm that modulation of TCR signaling could be mea-
sured through the magnitude T cell-mediated tumor cell
cytotoxicity in the co-culture assay. Lastly, we investigated the
effects of these targeted therapies on CD8+ T cell viability to
exclude direct effects on T cells. We found no significant differ-
ence in the viability of CD8+ T cells when treated with gefitinib
(320 nM), osimertinib (160 nM) (Supplementary Fig. S7A),
SCH58261 (10 µM) (Supplementary Fig. S7B) and dasatinib
(12.5 nM) (Supplementary Fig. S7C), at the same concentrations
and time points used in co-culture assays.
Together these data demonstrate that this novel co-culture
system can be easily applied to explore, how targeted therapies
may impact both the T cell and tumor cell compartments
across multiple donors, without the intrinsic variabilities nor-
mally observed with allogeneic responses.
Discussion
Understanding how CD8+ T cell anti-tumor immune responses
are conditioned by specific features of tumors such as their tissue
of origin and genotypes could aid in the development of success-
ful immunotherapy treatments. Within the tumor microenvir-
onment, this complex interaction is influenced by the presence
of a number of inhibitory and costimulatory surface molecules
on tumor cells and cytokines that can affect CD8+ T cell cyto-
toxic function.19 In the system described here, we propose an
in vitro approach to evaluate tumor cell sensitivity to CD8+
T cell-mediated cytotoxicity via their expression of anti-CD3
(OKT3). The ability of these engineered tumor cells to provide
‘signal 1ʹ to CD8+ T cells, thereby directly activating them,
bypasses the need for TCR recognition of specific MHC-
Figure 4. Expression levels of anti-CD3 influence the extent of tumor cell
cytotoxicity by T cells.
a. Representative histograms showing IgG hi, mid and lo gates on EGFRm PC-9
anti-CD3 expressing cells (dark grey histogram) compared to FMO controls (light
grey histogram), using flow cytometry staining with anti-IgG. b. Percentages of
live PC-9 anti-CD3 transduced cell lines when gating on IgG Hi, mid and lo tumor
cell expression after 18h co-cultures with restimulated CD8+ T cells. Data are
representative of two donors from three independent experiments (mean ±
SEM). EGFRm = epidermal growth factor receptor mutant; FMO = fluorescence
minus one control. **P < 0.01 and ****P < 0.0001, significant difference of % live
cells between anti-IgG Mid vs anti-IgG lo anti-IgG Hi vs anti-IgG lo at each E:
T ratio, assessed by two-way ANOVA and Sidak‘s multiple comparison test.
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peptide complexes on tumor cells, whilst still allowing for the
contributions of endogenous mechanisms of sensitivity and
resistance to be assessed. Thus far, assays that allow for simulta-
neous assessment of CD8+ T cell-mediated cytotoxicity of dif-
ferent cell lines across common donors are limited due to HLA
restriction and the variability associated with allogeneic
responses.5,6 Although not antigen-specific, our assay presents
a novel approach to investigating tumor escape strategies
between and within various cancer types, in anti-CD3 engi-
neered co-culture assays. In this paper, we specifically examined
Figure 5. Measurements of IFN-ɣ and early tumor cell apoptotic events provide additional sensitive pharmacodynamic endpoints in this assay system.
a. Percentages of live mock control cells versus anti-CD3 expressing PC-9, NCI-H1975 and NCI-H3255 EGFRm cell lines after 18h co-cultures with restimulated CD8+
T cells b. Percentages of annexin-V+ 7-AAD− (apoptotic) anti-CD3 expressing PC-9, NCI-H1975 and NCI-H3255 EGFRm cell lines after 18h co-cultures with CD8+ T cells.
c. Levels of IFN-ɣ production in supernatants from a. after 18h co-cultures of CD8+ T cells with mock and anti-CD3 expressing PC-9, NCI-H1975 and NCI-H3255 EGFRm
tumor cell lines. Data are representative of two donors from three independent experiments (mean ± SEM). EGFRm = epidermal growth factor receptor mutant. *P <
0.05, ***P < 0.0005 and ****P < 0.0001, significant difference of % live cells between mock and anti-CD3 at each E: T ratio, assessed by two-way ANOVA and Sidak‘s
multiple comparison test.
Figure 6. Investigating the impact of targeted therapies on T cell-mediated cytotoxicity using the anti-CD3-expressing tumor cell co-culture system.
Percentages of live PC-9 EGFRm anti-CD3 expressing cells after 18-h co-culture with restimulated CD8+ T cells a. with PC-9 pre-treatment with 360 nM Geftinib and
160 nM Osimertinib EGFR TKIs b. in the presence of 10 µM SCH68261 and c. in the presence of 12.5 nM Dasatinib, compared to DMSO controls. Data are
representative of two donors from two independent experiments (mean ± SEM), with two different donors used in each drug treatment experiment. EGFRm =
epidermal growth factor receptor mutant; EGFR TKIs = epidermal growth factor receptor tyrosine kinase inhibitors; DMSO ctrl = DMSO control. **P < 0.01, and ***P <
0.0005 and ****P < 0.0001, significant difference of % live cells between drug treatments and DMSO ctrl at each E: T ratio, assessed by two-way ANOVA and Sidak‘s
multiple comparison test.
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EGFRm NSCLC cell types and found a degree of variability in
their sensitivities to T cell-mediated cytotoxicity. The determi-
nants of these variations to T cell-mediated cytotoxicity will be
investigated in future studies. Such insight could lead to the
development of more personalized therapies in which the selec-
tion of drug treatments could potentially be based on tumor
genetics and predicted anti-tumor immune responses, using
assays such as the one described here.
Historically, the “gold standard” for measuring cytotoxicity
has been assays based on chromium (Cr51) released by the
lysed target cells.7 This method involves the use of radioactive
materials and the measurement of target cell death and has
low sensitivity in assays of cultures longer than 4–8h due to
the spontaneous release of Cr51.20,21 Alternatively, assays that
measure the release of endogenous enzymes22 and cytokines23
from co-culture supernatants indirectly measure cytotoxicity
and may not adequately compensate for the contribution of
effector cells in the readout.6,7 Our method relies on a flow
cytometry-based readout allowing for the evaluation of direct
T cell-mediated cytotoxicity by measuring tumor cell death.
Moreover, the method supports the analysis of the mechanism
of cell death, e.g. via measurement of annexin-V and 7AAD
on tumor cells and can provide insight into T cell viability and
phenotype following co-culture with target cells.
The generation of membrane-anchored anti-CD3 scFV
expressing cells has been previously described to create
immunosomes24 and stimulator cells,9 which both activate
human T cells. However, this is the first description of this
approach to directly engineer tumor cells to explore the cyto-
toxic potential of CD8+ T cells. We have shown that this
protocol is amenable to a variety of adherent tumor lines
and as such, can facilitate comparisons of tumor cell sensitiv-
ity across multiple tumor cells. Our data show that T cell-
mediated cytotoxicity of tumor cells is comparable to that of
P815 cells which express Fc receptors that allow TCR cross-
linking in the presence of soluble anti-CD3 (Figure 3b).
Whilst there remains some donor to donor variability in the
degree of cytotoxicity observed, this is reduced when com-
pared to assays that rely upon alloreactivity.8,25 However, it is
evident that the expression of anti-CD3 on tumor cell lines
leads to a larger cytotoxicity window compared to an allo-
geneic reaction (Figure 5 – anti-CD3 vs. mock controls). This
novel method provides a larger therapeutic window to evalu-
ate pharmacodynamic responses and increases assay through-
put by reducing the number of T cells required to elicit robust
cytotoxicity, both of which are limitations with standard allo-
geneic cytotoxicity assays. Moreover, our data demonstrate
that the T cell-mediated cytotoxicity observed in this assay is
specifically driven via anti-CD3 expression as empty vector
transduced (mock controls) cells undergo very little cell death
via allorecognition in this assay and failed to induce IFN-ɣ
production by CD8+ T cells when compared to co-cultures
with anti-CD3 expressing tumor cells.
To optimize and standardize the methods for preparation
of the CD8+ T cells used in the assay, we have characterized
both their function and phenotype during pre-activation as
well as during co-cultures. We have shown that a second
round of stimulation of T cells with anti-CD3/CD28 leads to
increased expression of CD45RO and loss of CD45RA and
CCR7, resulting in increased effector function indicated by
T cell-mediated cytotoxicity of P815 target cells (Figure 1a).
Within co-cultures, CD8+ T cell cytotoxic function was evi-
dent not only by the cell death of tumor cells but also the
significant production of granzyme B, in response to anti-CD
3 stimulation by tumor cells. Previous studies have shown that
on TCR crosslinking, stored granzyme B is released and there
is de novo synthesis of lytic proteins that refills these granules,
which are in turn secreted26 and might therefore explain our
results. PD-1 has important immunoregulatory roles in limit-
ing effective T cell responses.27 Traditionally, PD-1 has been
noted as one of the hallmarks of T cell exhaustion. However,
a broader view of PD-1 has highlighted its importance as
firstly, being a marker of T cell activation and secondly, its
expression correlating with TCR signaling strength.28 As such,
the induction of PD-1 expression in CD8+ T cells by anti-CD3
expressing tumor cells is expected and further shows the
physiological relevance of our system.
Previously published studies demonstrate that the level of
TCR engagement, e.g. by increased level of MHC/TCR clus-
tering, can influence the relative susceptibility of a target cell
to T cell-mediated cytotoxicity.29,30 In our assay system, we
describe a simple gating strategy to enable measurement of
the anti-CD3 expression levels on transduced cells in co-
cultures and show that this correlates with the amount of
T cell-mediated cytotoxicity observed. This is particularly
useful in manipulating the amount of cytotoxicity observed
in a single cell line, depending on the intended application of
the assay. One caveat of this novel method is differing trans-
duction efficiencies of tumor cells, which can result in varying
levels of anti-CD3 expression across different cell lines.
Therefore, this gating strategy allows cytotoxicity readouts to
be normalized via anti-CD3 expression across cell lines.
Targeted and immunotherapies have been extensively
investigated for their effects on cancer cells and in some
cases, immune cells. However, as it relates to CD8+ T cells,
most of these studies have evaluated their effects on assays
such as proliferation and cytokine production in vitro and
in vivo, which indirectly reflect cytotoxic function.31 We have
shown that our system directly allows the investigation of
therapies of interest on T cell cytolytic activity. We first
showed that EGFR TKIs result in an increase in target cell
death in PC-9 cells, which appears to be as a consequence of
their direct cytotoxic effect on the target cell and correlates
with the well-reported sensitivities of this cell line to EGFR
TKI based on its genotype.14 These results appear to be
additive in PC-9 and in a second EGFR mutant NSCLC cell
line, NCI-H3255 (also characterised to be sensitive to both
gefitinib and osimertinib)14 at lower E: T ratios, suggesting
that the effects of EGFR TKI treatment are diminished when
T cell-mediated cytotoxicity is increased in the presence of
higher numbers of CD8+ T cells. The reason for this is unclear
but there may be a maximum threshold of cytotoxicity mea-
surable in this assay. We also observed that SCH58261, an
inhibitor of adenosine A2a receptor (A2aR), increases T cell-
mediated cytotoxicity of target cells. Furthermore, this
increase of cytotoxicity with SCH58261 is consistent regard-
less of donor variability, and overall suggests that adenosine
could in fact influence T cell effector lytic function.32 We also
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showed that the Lck inhibitor, dasatinib, decreased the
amount of T cell-mediated cytotoxicity observed, showing
that our assay is amenable to both enhancing and suppressive
effects.
Overall, we have detailed a system that allows for engineer-
ing tumor cells to express anti-CD3 to measure their sensitiv-
ity to T cell-mediated cytotoxicity while also simultaneously
phenotyping CD8+ T cells and their responses, in an in vitro
co-culture assay. This system is highly adaptable to test dif-
ferent tumor cells, is reproducible across different donor
T cells and is both robust and sensitive permitting the evalua-
tion of novel drug combinations and interrogation of tumor
intrinsic mechanisms that may influence susceptibility to
T cell-mediated cytotoxicity.
Materials and methods
Generation of expression constructs encoding
membrane-bound anti-CD3 single chain fragments
cDNA derived from hybridoma cells producing the OKT3-
CD14 fusion protein (anti-CD3), was subjected to PCR ampli-
fication using primer pairs 5ʹ-TTCGAAGCCACCATGCCT
ATGGGCTC-3ʹ and 5ʹ-GGATCCTCAGGCGAAGCCTCT
AG-3ʹ designed with BstB1 sites on the 3ʹ end and BamH1
5ʹ end, digested and cloned into pCDH-UbC-MCS-EF1a-
Hygro to generate the lentiviral plasmid pCDH-UbC-CD14-
OKT3-EF1a-Hygro.
Cell culture and generation of anti-CD3 expressing tumor
cell lines – lentiviral transfection and transduction
For lentiviral transfection, 293T/17 packaging cells (ATCC)
were maintained in Dulbecco‘s Modified Eagle‘s Medium
(Gibco) supplemented with 10% heat-inactivated/gamma irra-
diated fetal bovine serum (FBS) (Invitrogen) and 1mM MEM
non-essential amino acids (Gibco) at 37⁰C and 5% CO2. At
70–90% confluence, 293T/17 cells were lentivirally transfected
with pCDH-UbC-CD14-OKT3-EF1a-Hygro expression plas-
mid or a pCDH-UBC-EF1a-Hygro empty plasmid (for mock
controls) and a master mix of packaging plasmids (pVSV-G,
pPACK-HI-GAG and Rev-pPACK-HI-REV) using lipofecta-
mine and Opti-MEM (Gibco). Supernatant containing lenti-
virus was collected 48 h later, filtered through a 0.2 µm filter
(EMD Millipore) and aliquots stored at −80⁰C for transduction
of tumor cells. A Lenti-X™ p24 Rapid Titer Kit (Clontech) was
used to determine lentiviral titers of collected supernatants. All
tumor cells were maintained in RPMI Medium 1640 –
GlutaMAX™-I (Gibco) supplemented with 10% FBS, at 37⁰C
and 5% CO2. PC-9, NCI-H1975 and NCI-H3255 EGFRm
tumor cells were grown to 80% confluence and were retrovirally
transduced using lentiviral supernatants at a multiplicity of
infection (MOI) of 1 and 10, based on p24 ELISA results, in
the presence of polybrene for 48 h. Positively expressing cells
were selected for using hygromycin B (Invitrogen) for 1 week,
cells were then maintained in hygromycin (30 µg/ml for PC-9
and NCI-H3255; 60 µg/ml for NCI-H1975), passaged and
bulked up for all experiments. Anti-CD3 transgene expression
was confirmed in cells transduced at a MOI of 1 and 10 by flow
cytometry staining and all future experiments were conducted
with cells transduced with an MOI of 1.
Sorting of anti-CD3 expressing tumor cell lines
Expression of CD14 membrane-bound anti-CD3 OKT3 scFV
on transduced cells was detected using either an Alexa Fluor®
647 AffiniPure Fab Fragment Goat anti-Mouse IgG (H + L)
antibody (Jackson Immunoresearch) or human CD14 PE-
conjugated antibody (R&D Systems). For sorting of trans-
duced cells, PC-9 NCI-H1975 and NCI-H3255 anti-CD3-
expressing cell lines were stained with human CD14 PE-
conjugated antibody (R&D Systems) and parental (non-anti-
CD3 expressing) cells were used as negative controls. PC-9,
NCI-H3255 and NCI-H1975 high expressing CD14 cells, with
overlapping expression levels, were gated for and sorted on
a FACS Aria sorter. Sorted cells were cultured in the presence
of hygromycin as before, passaged and bulked up for all
experiments.
CD8+ T cell isolation, activation, and expansion
PBMCs were isolated from blood from healthy volunteer
donors (National Health Service (NHS) blood and transplant
unit at Addenbrooke’s hospital) using density centrifugation
with Ficoll-Paque Plus (GE Healthcare). CD8+ T cells were
purified from PBMC using the EasySep™ Human CD8+ T Cell
Enrichment Kit (Stem Cell Technologies) and a RoboSep
(Stem Cell Technologies), according to the manufacturer’s
instructions. Isolated CD8+ T cells were activated with CD3/
CD28 dynabeads (Thermo Scientific) at a 1:1 ratio, cultured in
complete culture assay medium (DMEM- GlutaMAX™-I, 10%
FBS) supplemented with 1% penicillin-streptomycin and 100
U/ml IL-2 (Peprotech) and maintained at a density of 1 × 106
cells/ml, with medium changed every 2–3 days. On day 10,
CD8+ T cells were re-stimulated with CD3/CD28 dynabeads
as above with medium changes every 2–3 days.
CD8+ T cell cytotoxic assay
One day prior to co-culture assays (day 14 of CD8+ T cell activa-
tion), P815, PC-9, NCI-H1975, and NCI-H3255 tumor cells were
labeled with Vybrant DiO Cell-Labelling Solution (Thermo Fisher
Scientific) at a 1:200 dilution for 8 min, according to the manu-
facturer’s instructions. Cells were washed, resuspended at 2 × 105
cells/ml in culture assay medium and 50 µl/well (10,000 cells)
plated in 96 well-U-bottom plates. Plates were centrifuged and
incubated overnight at 37°C and 5% CO2. On day 15 of T-cell
activation, CD8+ T cells were harvested, dynabeads removed
magnetically and cells were resuspended at 1 × 106 cells/ml in
culture assay medium. For all co-cultures, CD8+ T cells were
added to respective wells of the U-bottom plate containing DiO-
labelled tumor cells at 1:1, 2:1, 5:1 and 10:1 effector: target (E: T)
ratios. Plates were centrifuged and incubated for either 4 or 18
h. After incubation, supernatants were removed and stored at
−80⁰C, wells were washed with PBS and cells were detached
with accutase and returned to the incubator for 10 min. Cells
were then transferred to a 96-well V-bottom plate and centri-
fuged. Harvested cells were stained with a LIVE/DEAD Fixable
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Violet Dead Cell Stain Kit (Thermo Scientific) at a dilution of
1:2500 in PBS for 10 min at room temperature. Cells were then
washed, fixed in 3.7% formaldehyde and data acquisition carried
out using a BD FACS Canto II or BD LSR Fortessa to analyze
Violet+ DiO – (live tumor cells). In some experiments, P815
mouse mastocytoma cells were used as controls to control for
T cell-mediated cytotoxicity capacity. P815 cells were DiO labeled
and plated as was done for tumor cells and were pre-treated with
0.5 µg/ml anti-CD3 (OKT3 clone) for 1 min (eBioscience) or an
isotype-matched control, before the addition of CD8+ T cells at
their respective ratios. Where indicated, staining with an Alexa
Fluor® 647 AffiniPure Fab Fragment Goat Anti-Mouse IgG (H +
L) antibody was also done in experiments to gate on cells with
similar anti-CD3 (OKT3) scFV expression levels9 (Jackson
ImmunoResearch). FITC Annexin-V Apoptosis Detection Kit
I (BD Biosciences) was used in experiments to analyze apoptotic
cell death in co-cultures. For co-culture experiments in the pre-
sence of EGFR tyrosine kinase inhibitors (TKIs), anti-CD3 tumor
cells were pre-treated with 320 nM Gefitinib and 160 nM
Osimertinib after being DiO-labelled, 24 h before the addition of
CD8+ T cells for 18 h. SCH58261 was added at a final concentra-
tion of 10 µM at the same time as the addition of the CD8+ T cells,
in the presence of 100 µM adenosine monophosphate (AMP)
(Sigma Aldrich). Experiments using dasatinib (AstraZeneca in-
house supply) were similarly carried out using a 12.5 nM con-
centration (as described by17) added at the same time as the CD8+
T cells. Dasatinib dose-response experiments were similarly
repeated using concentrations indicated. All drug concentrations
weremaintained throughout the 18h co-cultures. Flow cytometric
analysis was performed using a BD Fortessa. Data were analyzed
using FlowJo (Tree Star) as shown in Figure S1B.
T cell phenotyping
T cells were phenotyped by flow cytometry staining before (Day
0 – naïve and Day 10–10 days after 1st round of stimulation)
and after restimulation (Day 15), as well as in co-cultures with
tumor cells. Briefly, CD8+ T cells were stained with LIVE/
DEAD™ Fixable Blue Dead Cell Stain Kit (Thermo Scientific),
followed by surface staining at 4 ⁰C with: – anti-CD8 AF647,
anti-CD8 PerCPCy5.5, anti-CD45RO Alexa Fluor 488, anti-CD
45RA BV605, anti-CCR7-PE, anti-PD-1 PerCpCy5.5 (all from
Biolegend) antibodies. Staining of CCR7 was performed at 37
⁰C for 30 min. Intracellular granzyme B staining was performed
with anti-Granzyme B-AF647 antibody (Biolegend), after per-
meabilization with Fixation/Permeabilization Solution Kit (BD
Biosciences). Flow cytometric analysis was performed using
a BD Fortessa. Data were analyzed using FlowJo (Tree Star).
IFN-ɣ measurement
Supernatants from co-culture assays were stored at −80⁰C, prior
to analysis for IFN-ɣ production using the Human IFN-ɣ
DuoSet ELISA (R&D systems), according to the manufacturer’s
instructions. Plates were washed using a BioTek EL406 micro-
plate washer dispenser and read using an Envision L plate reader
(PerkinElmer).
Statistics
Two-way ANOVA and t-test were used to assess significance
using PRISM software. The P values are represented as ****P
< 0.0001 ***P < 0.001, **P < 0.01, *P < 0.05. The data are pre-
sented as mean ± standard error of the mean (SEM) or mean
± standard (SD) where indicated.
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